Bristol-Myers Squibb BMY Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenues by Product | ||||||
| Abraxane | $313M-59.0% | $368M-57.9% | $458M-51.7% | $637M-33.3% | $763M-22.3% | |
| Breyanzi | $1.51B+66.8% | $1.36B+81.8% | $1.23B+110% | $1.09B+142% | $903M+126% | |
| Camzyos | $1.22B+80.8% | $1.07B+77.6% | $938M+101% | $798M+111% | $677M+137% | |
| Cobenfy | $184M+397% | $155M+1,450% | $115M— | $72M— | $37M— | |
| Eliquis | $15.02B+13.9% | $14.44B+8.3% | $14.19B+9.0% | $13.44B+5.7% | $13.18B+5.4% | |
| Krazati | $207M+35.3% | $205M+62.7% | $188M+116% | $169M+219% | $153M+629% | |
| Opdivo Qvantig | $393M+4,267% | $239M— | $106M— | $39M— | $9M— | |
| Opdivo | $9.93B+4.6% | $10.05B+8.0% | $9.84B+6.8% | $9.66B+5.9% | $9.49B+6.8% | |
| Opdualag | $1.23B+26.1% | $1.19B+27.7% | $1.09B+26.0% | $1.02B+28.4% | $974M+36.0% | |
| Orencia | $3.75B+2.7% | $3.71B+0.6% | $3.7B+0.8% | $3.67B+0.4% | $3.65B+0.5% | |
| Other Growth products | $2.1B+15.1% | $2.03B+23.4% | $2.02B+39.9% | $1.95B+48.6% | $1.83B+45.2% | |
| Other Legacy products | $755M-15.7% | $798M-13.7% | $849M-6.3% | $897M-2.3% | $896M-5.1% | |
| Pomalyst/Imnovid | $2.59B-22.5% | $2.73B-22.9% | $2.86B-20.7% | $3.09B-13.9% | $3.34B-3.9% | |
| Reblozyl | $2.4B+26.7% | $2.33B+31.2% | $2.21B+42.8% | $2.04B+51.4% | $1.9B+64.1% | |
| Revlimid | $2.36B-53.1% | $2.95B-48.9% | $3.69B-37.3% | $4.53B-23.3% | $5.04B-16.2% | |
| Sotyktu | $304M+18.3% | $290M+17.9% | $288M+27.4% | $274M+21.2% | $257M+29.8% | |
| Sprycel | $392M-63.9% | $494M-61.6% | $612M-62.1% | $783M-57.5% | $1.09B-42.0% | |
| Yervoy | $2.93B+13.9% | $2.9B+14.7% | $2.77B+14.3% | $2.67B+13.2% | $2.57B+11.2% | |
| Zeposia | $588M+4.4% | $577M+1.9% | $576M+6.5% | $562M+8.7% | $563M+20.8% | |
| Total Revenues by Geography | ||||||
| International | $14.16B+8.0% | $13.83B+4.8% | $13.59B+3.1% | $13.38B+2.6% | $13.12B+0.5% | |
| Other | $1.13B+10.9% | $1.09B+9.1% | $1.13B+35.9% | $1.11B+49.1% | $1.02B+36.6% | |
| United States | $33.19B-0.9% | $33.28B-2.4% | $33.32B-0.3% | $33.22B+1.5% | $33.5B+5.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bristol-Myers Squibb break its business down?
- Bristol-Myers Squibb (BMY) reports total revenues by product across 20 parts — Abraxane, Breyanzi, Camzyos, Cobenfy and Eliquis. Each is extracted from the segment footnotes and tracked over time.
- Where does Bristol-Myers Squibb's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bristol-Myers Squibb's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
